Data from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

MLA

Frédéric Amant, et al. Data from Potential Targets’ Analysis Reveals Dual PI3K/MTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6526281.

APA

Frédéric Amant, Tjalling Bosse, Philippe Moerman, Els Hermans, Ellen Gommé, Debby Thomas, Godelieve Verbist, Miriam Mints, Eva Wardelmann, Michael R. Mallmann, Leonardus F. Massuger, Ronald P. Zweemer, Carole Mestdagh, Maciej Stukan, Helga B. Salvesen, Farid Moinfar, Johannes Haybaeck, Olli Carpén, Jutta Huvila, … Tine Cuppens. (2023). Data from Potential Targets’ Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative. https://doi.org/10.1158/1078-0432.c.6526281

Chicago

Frédéric Amant, Tjalling Bosse, Philippe Moerman, Els Hermans, Ellen Gommé, Debby Thomas, Godelieve Verbist, et al. 2023. “Data from Potential Targets’ Analysis Reveals Dual PI3K/MTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative,” March. doi:10.1158/1078-0432.c.6526281.